KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Retained Earnings (2017 - 2025)

Moderna (MRNA) has disclosed Retained Earnings for 9 consecutive years, with $7.2 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 28.09% to $7.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 billion through Dec 2025, down 28.09% year-over-year, with the annual reading at $7.2 billion for FY2025, 28.09% down from the prior year.
  • Retained Earnings for Q4 2025 was $7.2 billion at Moderna, up from $27.0 million in the prior quarter.
  • The five-year high for Retained Earnings was $18.4 billion in Q1 2023, with the low at -$370.0 million in Q4 2022.
  • Average Retained Earnings over 5 years is $6.9 billion, with a median of $6.2 billion recorded in 2021.
  • The sharpest move saw Retained Earnings skyrocketed 106296.32% in 2021, then crashed 18500.0% in 2022.
  • Over 5 years, Retained Earnings stood at -$24.0 million in 2021, then crashed by 1441.67% to -$370.0 million in 2022, then surged by 3777.3% to $13.6 billion in 2023, then fell by 26.17% to $10.0 billion in 2024, then dropped by 28.09% to $7.2 billion in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $7.2 billion, $27.0 million, and $23.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.